US company Moderna said it would record programs Monday for emergency approval of its Covid-19 vaccine in the United States and Europe, after full effects showed an estimated maximum efficacy of 94. 1%.
The long-awaited occurs when the United States prepares for an increase in supercharged coronavirus after Thanksgiving.
More than 265,000 Americans have died from and 93,000 have been hospitalized lately.
“Our vaccine will provide a tough new tool that can replace the course of this pandemic and help you avoid serious illness, hospitalizations and deaths,” said the company’s CEO, Stéphane Bancel.
If the U. S. Food and Drug Administration were to do so, it would not be able to do so. But it’s not the first time He says it is safe and effective, the first of two doses of the drug can be injected into the arms of millions of Americans until mid-December.
U. S. pharmaceutical company Pfizer and Germany’s BioNTech sought similar approvals last week, and their vaccine may light up in the US. But it’s not the first time Shortly after December 10.
The Modern vaccine, which evolved together with the US National Institutes of Health, has evolved together with the US National Institutes of Health. Usa, it is being studied in a clinical trial with more than 30,000 participants in the United States.
A provisional investigation announced earlier this month was based on 95 patients who became ill with Covid-19.
The final research was based on 196 cases, of which 185 were observed in a placebo-winning organization compared to 11 who won the injections.
Thirty other people had severe cases, all in the placebo organization, which also included a deceased person.
Significantly, the effectiveness is uniform across age, race, ethnicity and gender, the company said.
The 196 instances of Covid-19 included 33 adults over the age of 65 and 42 participants known as community members (including 29 Hispanics, six blacks, 4 Asian-Americans, and 3 multiracials).
Modern Headquarters in Cambridge, Massachusetts – The company will register an emergency authorization application for its Covid-19 vaccine in the United States and Europe Photo: AFP / Joseph Prezioso
The vaccine has been well tolerated, with maximum non-unusual side effects, adding injection site pain, fatigue, muscle pain, joint pain, headaches and redness at the site.
These are higher in frequency and severity after the dose in the vaccinated group.
The press release included the line: “No new serious protection disorders have been known through the company”; however, he explicitly indicated whether serious disorders had previously been reported.
External experts welcomed the new findings, in the absence of severe cases of Covid-19 in the vaccinated group.
“Serious disease prevention and hospitalization can be expected to put pressure on overburdened fitness services, provided that a sufficient proportion of the high-risk population can be vaccinated,” said Penny Ward, visiting professor of pharmaceutical medicine at King’s College London.
Modern and Pfizer vaccines are based on a new generation that uses mRNA (messenger ribonucleic acid) to deliver genetics to the framework that allows human cells to produce a protein from the virus.
This causes the immune formula to be able to attack if it encounters SARS-CoV-2.
But the Modern vaccine can be kept long-term at -20 degrees Celsius (-4 degrees Fahrenheit) while the Pfizer vaccine requires -70 degrees Celsius (-94 degrees Fahrenheit).
Moderna said it expects to have about 20 million doses of the vaccine, called mRN-1273, in the United States until the end of the year.
It plans to manufacture 500 million to one billion doses internationally until 2021.
American scientist Anthony Fauci warned Sunday of a “rocket” in Covid-19 after millions of Americans traveled and socialized during the Thanksgiving vacation.